March 23, 2010 – The FDA granted approval for diltiazem hydrochloride extended-release tablets to treat hypertension, which is the generic equivalent to Biovail Laboratories International SRL's Cardizem LA product.
Watson Pharmaceuticals Inc. will produce the generic drug and plans for its immediate release. For the 12-months ending Dec. 31, 2009, Cardizem LA had total U.S. sales of approximately $94.1 million, according to IMS Health.
For more information: www.watson.com
July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...
July 10, 2024 
June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...
June 05, 2024 
May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...
May 24, 2024 
May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...
May 06, 2024 
February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...
February 16, 2024 
January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...
January 25, 2024 
January 12, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...
January 12, 2024 
November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...
November 21, 2023 
In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...
October 25, 2023 
In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...
September 26, 2023